BPC-157 Safety Evaluation for Wound Treatment

BPC-157 is the essential activity fragment of the BPC peptide found in human gastric juice. The pentadecapeptide BPC-157, composed of 15 amino acids, has been shown to promote the healing of wounds and traumas in various organs and tissues. The application of this body-protective compound has endless possibilities for the healing of damage found in the esophagus, stomach, duodenum, and colorectal mucosa. BPC-157 is a naturally occurring cell/organ protectant for the stomach as a stress coping response meant to heal the body’s extragastrointestinal tissues [3].

This gastric peptide is reported to be cytoprotective, meaning it has the capacity to stimulate mucus production and enhance blood flow. Indicating BPC-157’s effectiveness for promoting healing. Studies suggest that it has strong potential as a therapeutic agent for trauma and stress damage in multiple organs; such as the liver, pancreas, ligaments, muscles, cornea, heart, and nerves [4]. 

Protective Effect of BPC-157

Various studies have observed the role BPC-157 has on pathological changes in the damage of various organs. The topical use of BPC-157 shows considerably faster-wound closure than wounds left untreated (Figure 1). Typically the accelerating effects that BPC-157 has on wound healing is significant after 12 days of treatment, indicating the clinical application of this peptide is necessary for at least a two-week trial [2]. 

BPC-157’s main function is to accelerate the repair of various tissues. Use of BPC-157 has demonstrated to be effective in treating tissue damage because it is able to quickly restore blood supply to an ischemically injured area and will rapidly activate collaterals. It is unlike other cytoprotective agents that only display prophylactic effectiveness, BPC-157 has both prophylactic and therapeutic ability [1].

The topical use of BPC-157 shows considerably faster wound closure than wounds left untreated
(Figure 1) The topical use of BPC-157 shows considerably faster-wound closure than wounds left untreated [2].

BPC-157 Safety

Recent preclinical safety evaluations on BPC-157 have been achieved. This preclinical animal study demonstrates the clinical trial worthiness and safety of BPC-157. The Toxicology data obtained from the present study revealed that BPC-157 was well tolerated at high doses and that the detected clinical and pathological changes were within normal ranges. The single injection of 100 μg/mL BPC157 into the quadriceps femoris of rabbits did not induce irritant symptoms at the injection sites (figure 2A) or any significant allergenicity in the skin (figure 2B & 2C). These local tolerance studies indicate that the administration of BPC-157 is safe [4].

This study aimed to uncover the potential harm that could occur from BPC-157 treatment. Since BPC-157 has versatile applications for the treatment of various wounds across a multitude of organs, it remains to be a promising agent for the clinical trials of diversified applications.  

The single injection of 100 μg/mL BPC157 into the quadriceps femoris of rabbits did not induce irritant symptoms at the injection sites (figure 2A) or any significant allergenicity in the skin (figure 2B & 2C)
(Figure 2) The single injection of 100 μg/mL BPC157 into the quadriceps femoris of rabbits did not induce irritant symptoms at the injection sites (figure 2A) or any significant allergenicity in the skin (figure 2B & 2C)[4].

In Conclusion 

Preclinical trials on various species have indicated that BPC-157 can be a useful prototype for a new class of drugs. The multifunctional body-protective application of BPC-157 is a more appropriate choice compared to widely used cytokine drugs for the treatment of wounds and tissue damage. Now known that BPC-157 was found to be safe in pre-clinical trials, the next step is the clinical study of this peptide. Moving forward there needs to be a clinical application of BPC-157 on the treatment of various wounds.

References

  1. A. Duzel, J. Vlainic, M. Antunovic, D. Malekinusic, B. Vrdoljak, et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World J. Gastroenterol., 23 (2017), pp. 8465-8488 https://www.wjgnet.com/1007-9327/full/v23/i48/8465.htm
  2. T. Huang, K. Zhang, L. Sun, X. Xue, C. Zhang, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des. Dev. Ther., 9 (2015), pp. 2485-2499 https://www.ncbi.nlm.nih.gov/pubmed/25995620
  3. Predrag Sikiric*, Sven Seiwerth, Rudolf Rucman, Domagoj Drmic, Mirjana Stupnisek, Antonio Kokot, Marko Sever, Ivan Zoricic, Zoran Zoricic, Lovorka Batelja, Tihomil Ziger, Kresimir Luetic, Josipa Vlainic, Zarko Rasic and Martina Lovric Bencic, “Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?”, Current Pharmaceutical Design (2017) 23: 4012. https://doi.org/10.2174/1381612823666170220163219
  4. Xu, C., Sun, L., Ren, F., Huang, P., Tian, Z., Cui, J., … Li, W. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 104665. https://doi.org/https://doi.org/10.1016/j.yrtph.2020.104665

More To Explore

Contact Us

Address: 539 W. Commerce St #1360, Dallas, TX 75208
Phone: 855-696-4937
Email: [email protected]

© 2020 Preventive Medicine. All Rights Reserved.

Close

Mickey Karram, MD

Dr. Karram is an internationally renowned urogynecologist and pelvic surgeon. He is board certified in Obstetrics and Gynecology as well as Female Pelvic Medicine and Reconstructive Surgery.  He completed his fellowship training in Urogynecology at Harbor UCLA School of Medicine. He is the Honorary Editor-In-Chief of the International Urogynecology Journal and the consumer publication Female Health Today, as well as the  past president of the American Urogynecology Society.

He has published more than 200 scientific articles and book chapters and has co-authored numerous textbooks including, “Urogynecology and Reconstructive Pelvic Surgery,”  the “Atlas of Pelvic Anatomy and Gynecologic Surgery” along with a series of eight books entitled “Female Pelvic Surgery Video Atlas.”

Dr Karram has directed numerous  post-graduate teaching courses throughout the United States and abroad. He has been invited to lecture and perform demonstration surgeries throughout the United States, Europe, Asia, South America and Australia. Dr Karram has been designated by Good Housekeeping magazine as one of the “Best Doctors in America for Women.” He and his wife Mona co-founded the national, not-for-profit, Foundation for Female Health Awareness, which raises funds to support education and research for women’s health.

Become a Founding Member Today!

Membership is Free through 12/31/2021

Join Now!
X